RAD51 wrestles with SUMO

IF 2.6 Q3 ONCOLOGY

Molecular and Cellular Oncology Pub Date : 2022-03-31 DOI:10.1080/23723556.2022.2054263

Y. Kee, Jung-Hee Lee, H. You

引用次数: 0

Abstract

ABSTRACT RAD51 loading onto chromatin is a key step during the homologous recombination (HR) repair. We recently reported a new mode of RAD51 regulation, which is mediated by TOPORS E3 SUMO ligase and RAD51 SUMOylation. ATM/ATR-induced phosphorylation of TOPORS is necessary for this event, revealing a new role of these master DNA damage response kinases in HR repair.

查看原文本刊更多论文

RAD51与相扑摔跤

RAD51在染色质上的负载是同源重组（HR）修复过程中的关键步骤。我们最近报道了一种新的RAD51调节模式，该模式由TOPORS E3 SUMO连接酶和RAD51 SUMO化介导。ATM/ATR诱导的TOPORS磷酸化对于这一事件是必要的，揭示了这些主DNA损伤反应激酶在HR修复中的新作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular and Cellular Oncology Biochemistry, Genetics and Molecular Biology-Cancer Research

CiteScore

3.20

自引率

0.00%

发文量

期刊介绍： For a long time, solid neoplasms have been viewed as relatively homogeneous entities composed for the most part of malignant cells. It is now clear that tumors are highly heterogeneous structures that evolve in the context of intimate interactions between cancer cells and endothelial, stromal as well as immune cells. During the past few years, experimental and clinical oncologists have witnessed several conceptual transitions of this type. Molecular and Cellular Oncology (MCO) emerges within this conceptual framework as a high-profile forum for the publication of fundamental, translational and clinical research on cancer. The scope of MCO is broad. Submissions dealing with all aspects of oncogenesis, tumor progression and response to therapy will be welcome, irrespective of whether they focus on solid or hematological neoplasms. MCO has gathered leading scientists with expertise in multiple areas of cancer research and other fields of investigation to constitute a large, interdisciplinary, Editorial Board that will ensure the quality of articles accepted for publication. MCO will publish Original Research Articles, Brief Reports, Reviews, Short Reviews, Commentaries, Author Views (auto-commentaries) and Meeting Reports dealing with all aspects of cancer research.